SRC points the way to biomarkers and chemotherapeutic targets.
SRC points the way to biomarkers and chemotherapeutic targets.
复制标题
DOI：
10.1177/1947601912458583
复制
发表时间：
2012-05-01
期刊：
影响因子：
--
通讯作者：
Goldberg, Gary S
中科院分区：
文献类型：
--
作者：
Krishnan, Harini;Miller, W Todd;Goldberg, Gary S
自从一百多年前Peyton Rous的工作以来，Src在肿瘤发生中的作用已经得到了广泛的研究。SRC是一种非受体酪氨酸激酶，在控制肿瘤细胞生长和迁移的信号通路中发挥关键作用。SRC调节大量分子的活性以诱导细胞转化。然而，转化的细胞并不总是迁移并实现其致瘤潜力。它们可以通过一种称为接触正常化的过程，通过包围未转化的细胞来正常化。肿瘤细胞需要超越接触正常化才能变得恶性或转移。在这篇综述中，我们讨论了Src在细胞迁移和接触正常化中的作用，重点讨论了Cas和Abl途径。这一范例阐明了几个化疗靶点，并可能导致识别新的生物标记物和开发有效的抗癌治疗方法。
The role of Src in tumorigenesis has been extensively studied since the work of Peyton Rous over a hundred years ago. Src is a non-receptor tyrosine kinase that plays key roles in signaling pathways controlling tumor cell growth and migration. Src regulates the activities of numerous molecules to induce cell transformation. However, transformed cells do not always migrate and realize their tumorigenic potential. They can be normalized by surrounding nontransformed cells by a process called contact normalization. Tumor cells need to override contact normalization to become malignant or metastatic. In this review, we discuss the role of Src in cell migration and contact normalization, with emphasis on Cas and Abl pathways. This paradigm illuminates several chemotherapeutic targets and may lead to the identification of new biomarkers and the development of effective anticancer treatments.